Alpha Teknova Inc (TKNO) is a leading entity in the synthetic biology sector, specializing in the production of vital biological reagents and supplements that cater to life sciences research and biomanufacturing. The company's offerings play a pivotal role in high-demand areas such as vaccine development, cell and gene therapy, and diagnostic testing, underscored by a commitment to quality and exceptional customer service. With a robust biotechnology foundation and a strong focus on innovation, Alpha Teknova is well-equipped to capitalize on growth opportunities in the rapidly evolving life sciences market, positioning itself as a valuable investment for institutional stakeholders.
| Revenue (TTM) | $41.80M |
| Gross Profit (TTM) | $14.22M |
| EBITDA | $-9.47M |
| Operating Margin | -38.80% |
| Return on Equity | -23.90% |
| Return on Assets | -9.29% |
| Revenue/Share (TTM) | $0.78 |
| Book Value | $1.28 |
| Price-to-Book | 3.20 |
| Price-to-Sales (TTM) | 4.99 |
| EV/Revenue | 5.22 |
| EV/EBITDA | -6.23 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 13.10% |
| Shares Outstanding | $53.61M |
| Float | $10.88M |
| % Insiders | 9.32% |
| % Institutions | 84.73% |
Volatility is currently contracting